Hims & Hers is evolving beyond its original focus, aggressively expanding into peptides and GLP-1. Read why I reiterate my ...

If you are looking to get a weight loss drug but lack insurance coverage, telehealth websites such as Ro, Hers and Mochi Health sell GLP-1 drugs for lower prices than what you’d pay at a pharmacy, ...

HIMS showcases outstanding financial strength. With just $63 million in debt against a market value of $13 billion, the ...

Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...

Hims & Hers Health Inc. is cutting more than 4% of its workforce as it pivots away from selling cheap copycat versions of ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Hims & Hers Health continues to fire on all cylinders as a business. Click here to read why HIMS stock is a Buy.

Online health and wellness company Hims & Hers raised $1 billion through convertible senior notes to grow its international ...

Investors are buying Hims & Hers Health ( HIMS 10.09%) stock hand over fist after the mail-order drugs company reported an earnings miss but a sales beat last night. But they're selling off shares of ...

Hims & Hers teams up with Novo Nordisk to bundle Wegovy into a $599/month telehealth care plan. Investors see Amazon-like potential as Hims scales affordable healthcare through platform-based ...